Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

被引：0
|
作者：
Felip, Enriqueta
Doger, Bernard
Majem, Margarita
Carcereny, Enric
Krebs, Matthew
Peguero, Julio Antonio
Roxburgh, Patricia
Forster, Martin
Bajaj, Pawan
Clay, Timothy Dudley
Triebel, Frederic
机构：
[1] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[3] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[4] Hosp Badalona Germans Trias & Pujol, B ARGO Grp Badalona Appl Res Grp Oncol, Catalan Inst Oncol, Med Oncol Dept, Badalona, Spain
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[7] Oncol Consultants PA, Dept Res, Houston, TX USA
[8] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[9] UCL Canc Inst, London, England
[10] Univ Coll London Hosp, London, England
[11] Griffith Univ, Brisbane, Qld, Australia
[12] St John God Hosp, Perth, WA, Australia
[13] Immutep, Res & Dev, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3100
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
    Forster, Martin
    Brana, Irene
    Pousa, Antonio L.
    Doger, Bernard
    Roxburgh, Patricia
    Bajaj, Pawan
    Peguero, Julio
    Krebs, Matthew
    Carcereny, Enric
    Patel, Grisma
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3726 - 3734
  • [22] FEASIBILITY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) COMBINED WITH STANDARD-OF-CARETHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) ADENOCARCINOMAS. INITIAL RESULTS FROM INSIGHT-003
    Atmaca, Akin
    Mueller, Daniel W.
    Habibzade, Timursah
    Schaaf, Marina
    Klagges, Jorge
    Eickhoff, Regina
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    Goetze, Thorsten O.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A604 - A604
  • [23] INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
    Atmaca, A.
    Mueller, D. W.
    Habibzada, T.
    Schaaf, M.
    Klagges, J.
    Eickhoff, R.
    Jaeger, E.
    Al-Batran, S-E.
    Goetze, T. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S632 - S632
  • [24] Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
    Wildiers, Hans
    Armstrong, Anne
    Cuypere, Eveline
    Dalenc, Florence
    Dirix, Luc
    Chan, Steve
    Marme, Frederik
    Schroder, Carolina P.
    Huober, Jens
    Duhoux, Francois P.
    Vuylsteke, Peter
    Jager, Agnes
    Brain, Etienne
    Kuemmel, Sherko
    Papai, Zsuzsanna
    van Oordt, Catharina Willemien Menke-van der Houven
    Perjesi, Luca
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    CLINICAL CANCER RESEARCH, 2024, 30 (03) : 532 - 541
  • [25] Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
    Tsao, Anne S.
    Liu, Suyu
    Fujimoto, Junya
    Wistuba, Ignacio I.
    Lee, J. Jack
    Marom, Edith M.
    Charnsangavej, Chusilp
    Fossella, Frank V.
    Tran, Hai T.
    Blumenschein, George R.
    Papadimitrakopoulou, Vassiliki
    Kies, Merrill S.
    Hong, Waun K.
    Stewart, David J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2104 - 2111
  • [26] Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II
    Duhoux, Francois P.
    Jager, Agnes
    Dirix, Luc Yves
    Huizing, Manon Thirza
    Jerusalem, Guy Heinrich Maria
    Vuylsteke, Peter
    De Cuypere, Eveline
    Breiner, Doris
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
    Krebs, Matthew G.
    Forster, Martin
    Majem, Margarita
    Peguero, Julio
    Iams, Wade
    Clay, Tim
    Roxburgh, Patricia
    Doger, Bernard
    Bajaj, Pawan
    Barba, Andres
    Perera, Suvini
    Mueller, Christian
    Triebel, Frederic
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
  • [28] A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non-small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab.
    Qin, Angel
    Morgensztern, Daniel
    Waqar, Saiama Naheed
    Owen, Dwight Hall
    Gadgeel, Shirish M.
    Kalemkerian, Gregory Peter
    Zhao, Lili
    Ramnath, Nithya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+HER2-metastatic breast cancer
    Marme, F.
    Wildiers, H.
    Dirix, L.
    Armstrong, A.
    De Cuypere, E.
    Dalenc, F.
    Schroder, C. Pia
    Vuylsteke, P.
    Brain, E.
    Kuemmel, S.
    Papai, Z.
    Mueller, C.
    Brignone, C.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S203 - S204
  • [30] A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
    Chen, Yuh-Min
    Yu, Chong-Jen
    Yang, Chih-Hsin
    Perng, Reury-Perng
    Tsai, Chun-Ming
    Shih, Jen-Fu
    Cheng, Ann-Lii
    Lefresne, F.
    Barbier, M.
    Pouget, J.-C.
    Yang, Pan-Chyr
    LUNG CANCER, 2007, 56 (01) : 89 - 95
12345